PARATHAR Drug Patent Profile
✉ Email this page to a colleague
When do Parathar patents expire, and when can generic versions of Parathar launch?
Parathar is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in PARATHAR is teriparatide acetate. There are four drug master file entries for this compound. Additional details are available on the teriparatide acetate profile page.
Summary for PARATHAR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 10 |
Patent Applications: | 1,432 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PARATHAR at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for PARATHAR
US Patents and Regulatory Information for PARATHAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | PARATHAR | teriparatide acetate | INJECTABLE;INJECTION | 019498-001 | Dec 23, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |